Clinical Trial Detail

NCT ID NCT03860844
Title Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Sanofi
Indications

acute myeloid leukemia

childhood acute lymphocytic leukemia

Therapies

Idarubicin

Cyclophosphamide

Isatuximab

Doxorubicin

Etoposide

Daunoxome

Cytarabine

Methotrexate

Daunorubicin

Fludarabine

Dexamethasone

Mitoxantrone

Filgrastim

Vincristine Sulfate

Pegaspargase

Age Groups: child

No variant requirements are available.